In an adult patient with acute coronary syndrome who has normal renal function (creatinine clearance ≥30 mL/min) and no high‑risk bleeding, is enoxaparin preferred over unfractionated heparin as the anticoagulant?

Enoxaparin vs Unfractionated Heparin in ACS

In adult ACS patients with normal renal function (CrCl ≥30 mL/min) and no high-risk bleeding, enoxaparin is preferred over unfractionated heparin (UFH) for initial anticoagulation, offering similar or superior efficacy with more predictable dosing and lower risk of heparin-induced thrombocytopenia. However, UFH remains the preferred choice when percutaneous coronary intervention (PCI) is imminent or planned, due to its reversibility and established use during procedures 1.

Guideline Recommendations

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide nuanced direction on this question 1:

• For initial medical management: Both agents are acceptable, but enoxaparin offers practical advantages with subcutaneous dosing (1 mg/kg every 12 hours) versus UFH's continuous IV infusion requiring aPTT monitoring (60-80 seconds target range)

• For PCI support: Intravenous enoxaparin receives a Class 2b recommendation (may be considered) as an alternative to UFH to reduce ischemic events, but UFH traditionally remains preferred 1

• Key limitation: Multiple meta-analyses in NSTE-ACS have not demonstrated compelling superiority of enoxaparin over UFH in efficacy, though some data favor enoxaparin 1

Evidence Quality and Nuances

The 2025 guidelines explicitly state: "In NSTE-ACS, despite some data favoring the use of enoxaparin over UFH, multiple meta-analyses have not demonstrated compelling superiority in efficacy over UFH" 1. This represents a more conservative interpretation than older data suggested.

However, the INTERACT trial (high-quality evidence) demonstrated that in high-risk NSTE-ACS patients receiving eptifibatide, enoxaparin compared to UFH resulted in 2:

• Significantly less major bleeding (1.8% vs 4.6%, p=0.03)
• Less early myocardial ischemia (14.3% vs 25.4%, p=0.0002)
• Lower 30-day death or MI (5% vs 9%, p=0.031)
• These benefits persisted at 2.5-year follow-up 3

The SYNERGY trial (largest trial, 10,027 patients) showed enoxaparin was noninferior but not superior to UFH in high-risk patients managed invasively, with modestly increased TIMI major bleeding (9.1% vs 7.6%, p=0.008) 4.

Practical Decision Algorithm

Choose Enoxaparin when:

• Conservative/delayed invasive strategy planned (>24-48 hours)
• Patient requires predictable anticoagulation without continuous monitoring
• Concern for heparin-induced thrombocytopenia (lower risk with enoxaparin) 5
• Subcutaneous administration preferred for nursing workflow
• Dose: 1 mg/kg subcutaneous every 12 hours 1

Choose UFH when:

• Immediate PCI planned (within hours)
• Need for rapid reversibility with protamine 1
• Activated clotting time (ACT) monitoring during PCI desired (target 250-300 seconds) 1
• Patient has severe renal impairment approaching CrCl <30 mL/min threshold
• Dose: 60 IU/kg bolus (max 4000 IU), then 12 IU/kg/h infusion (max 1000 IU/h) 1

Critical Safety Considerations

Enoxaparin-specific risks:

• Cannot be fully reversed (protamine only partially effective)
• Requires dose adjustment if CrCl <30 mL/min (reduce to 1 mg/kg daily) 1
• If switching from enoxaparin to PCI: timing matters—if last dose was <8 hours ago, give no additional enoxaparin; if 8-12 hours ago, give 0.3 mg/kg IV 1
• Real-world data shows increased major bleeding in elderly (≥65 years), those with bleeding history, or on oral anticoagulants 6

UFH-specific risks:

• Heparin-induced thrombocytopenia (HIT) risk—monitor platelet counts; discontinue if <100,000/mm³ 7
• Unpredictable pharmacokinetics requiring frequent aPTT monitoring 1
• Higher nursing burden with continuous infusion management

Common Pitfalls to Avoid

1. Switching anticoagulants mid-treatment: The SYNERGY trial showed increased bleeding when patients crossed over between agents 4. Choose one and stick with it unless compelling reason to switch.

2. Using fondaparinux for PCI: Absolutely contraindicated due to catheter thrombosis risk (0.9% vs 0.3% with enoxaparin) 1. If patient on fondaparinux proceeds to PCI, must add full-dose UFH 5.

3. Ignoring renal function: Enoxaparin accumulates with CrCl <30 mL/min—must reduce to once-daily dosing 1.

4. Premature discontinuation: Stopping anticoagulation causes rebound thrombin activity with reinfarction risk highest at 4-8 hours post-discontinuation 1.

The 2021 ESC Perspective

The European guidelines note that enoxaparin has "a predictable dose-effect relationship and lower risk for HIT compared to UFH" and "should be considered as an anticoagulant for PCI in patients pre-treated with subcutaneous enoxaparin," though they acknowledge "dedicated large-scale trials comparing enoxaparin vs. UFH in NSTE-ACS are lacking" 5.

Cost-Effectiveness Data

Real-world analysis of over 1 million ACS patients showed enoxaparin associated with cost savings of $2,475-$3,050 per patient compared to UFH, driven by reduced complications and shorter length of stay 8. This supports enoxaparin as the economically dominant strategy when clinically appropriate.

Bottom line: Start with enoxaparin for medical management unless PCI is imminent, then use UFH for procedural support with its established ACT-guided dosing and reversibility.